Payment overview · 2025
General Payments
$637.28
18 reported records · 9 companies
Healthcare provider profile · identity verified
Kevin E Sherer, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · BEND, OR · NPI 1922097039
Verified facts
What the public records show
CMS Open Payments records show Kevin E Sherer, MD received $637.28 in general payments during 2025 across 18 reported records.
Actelion Pharmaceuticals US, Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Uptravi.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Uptravi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ofev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $246.44 | 38.7% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $140.46 | 22.0% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $62.15 | 9.8% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $43.12 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.01 | 6.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.82 | 6.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.25 | 4.4% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $18.97 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.06 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $619.90 | 17 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $246.44 | 5 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $141.87 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $140.46 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $79.73 | 3 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $45.80 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $38.82 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $35.48 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 519 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 327 | 120 |
| Prednisone | Prednisone | 201 | 74 |
| Breo Ellipta | Fluticasone/Vilanterol | 183 | 45 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 176 | 58 |
| Spiriva Respimat | Tiotropium Bromide | 163 | 33 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 158 | 34 |
| Montelukast Sodium | Montelukast Sodium | 124 | 34 |
| Azithromycin | Azithromycin | 119 | 58 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 111 | 41 |
| Ambrisentan | Ambrisentan | 100 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 97 | 22 |
| Roflumilast | Roflumilast | 89 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 85 | 23 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 85 | 17 |
| Trazodone Hcl | Trazodone Hcl | 75 | 22 |
| Eliquis | Apixaban | 74 | 15 |
| Furosemide | Furosemide | 74 | 17 |
| Tadalafil | Tadalafil | 63 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 61 | 20 |
| Spironolactone | Spironolactone | 61 | 14 |
| Ofev | Nintedanib Esylate | 59 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 56 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | 16 |
| Prazosin Hcl | Prazosin Hcl | 42 | suppressed |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Dulera | Mometasone/Formoterol | 36 | suppressed |
| Gabapentin | Gabapentin | 36 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Pirfenidone | Pirfenidone | 35 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Uptravi | Selexipag | 19 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 12 |
| Lorazepam | Lorazepam | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Winrevair | Sotatercept-Csrk | 14 | suppressed |
| Lisinopril | Lisinopril | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Adempas | Riociguat | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Trikafta | Elexacaftor/Tezacaftor/Ivacaft | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $637.28 · 18 records | Actelion Pharmaceuticals US, Inc. | AIRSUPRA, Arikayce, Brinsupri, FASENRA, INSPIRE, JASCAYD, OPSUMIT, OPSYNVI, Ohtuvayre, Remodulin, TEZSPIRE, Tyvaso, UPTRAVI, t:slim X2 Insulin Pump with Control-IQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Uptravi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error